Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bellicum Pharmaceuticals stock | 2.85

Own Bellicum Pharmaceuticals stock in just a few minutes.


Fact checked

Bellicum Pharmaceuticals, Inc is a biotechnology business based in the US. Bellicum Pharmaceuticals shares (BLCM) are listed on the NASDAQ and all prices are listed in US Dollars. Bellicum Pharmaceuticals employs 107 staff and has a trailing 12-month revenue of around USD$5.2 million.

How to buy shares in Bellicum Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Bellicum Pharmaceuticals. Find the stock by name or ticker symbol: BLCM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bellicum Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.85, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Bellicum Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Bellicum Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Bellicum Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Bellicum Pharmaceuticals's share price has had significant negative movement.

Its last market close was USD$2.85, which is 69.02% down on its pre-crash value of USD$9.2 and 147.83% up on the lowest point reached during the March crash when the shares fell as low as USD$1.15.

If you had bought USD$1,000 worth of Bellicum Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$2,669.10 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,095.58.

Bellicum Pharmaceuticals share price

Use our graph to track the performance of BLCM stocks over time.

Bellicum Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$2.85
52-week range USD$0.7211 - USD$12.15
50-day moving average USD$6.3869
200-day moving average USD$6.8156
Wall St. target price USD$17.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.314

Buy Bellicum Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bellicum Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bellicum Pharmaceuticals price performance over time

Historical closes compared with the close of $2.85 from 2020-11-16

1 week (2020-11-20) -6.25%
1 month (2020-10-30) -23.18%
3 months (2020-08-28) -53.96%
6 months (2020-05-29) -62.65%
1 year (2019-11-29) 228.64%
2 years (2018-11-29) -31.49%
3 years (2017-11-29) -70.77%
5 years (2015-11-27) -87.82%

Bellicum Pharmaceuticals financials

Revenue TTM USD$5.2 million
Gross profit TTM USD$-55,328,000
Return on assets TTM -50.42%
Return on equity TTM -6120.17%
Profit margin 0%
Book value $0.248
Market capitalisation USD$32.9 million

TTM: trailing 12 months

Shorting Bellicum Pharmaceuticals shares

There are currently 444,556 Bellicum Pharmaceuticals shares held short by investors – that's known as Bellicum Pharmaceuticals's "short interest". This figure is 35.8% up from 327,470 last month.

There are a few different ways that this level of interest in shorting Bellicum Pharmaceuticals shares can be evaluated.

Bellicum Pharmaceuticals's "short interest ratio" (SIR)

Bellicum Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Bellicum Pharmaceuticals shares currently shorted divided by the average quantity of Bellicum Pharmaceuticals shares traded daily (recently around 116988.42105263). Bellicum Pharmaceuticals's SIR currently stands at 3.8. In other words for every 100,000 Bellicum Pharmaceuticals shares traded daily on the market, roughly 3800 shares are currently held short.

However Bellicum Pharmaceuticals's short interest can also be evaluated against the total number of Bellicum Pharmaceuticals shares, or, against the total number of tradable Bellicum Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bellicum Pharmaceuticals's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Bellicum Pharmaceuticals shares in existence, roughly 90 shares are currently held short) or 0.0881% of the tradable shares (for every 100,000 tradable Bellicum Pharmaceuticals shares, roughly 88 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bellicum Pharmaceuticals.

Find out more about how you can short Bellicum Pharmaceuticals stock.

Bellicum Pharmaceuticals share dividends

We're not expecting Bellicum Pharmaceuticals to pay a dividend over the next 12 months.

Have Bellicum Pharmaceuticals's shares ever split?

Bellicum Pharmaceuticals's shares were split on a 1:10 basis on 6 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellicum Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Bellicum Pharmaceuticals shares which in turn could have impacted Bellicum Pharmaceuticals's share price.

Bellicum Pharmaceuticals share price volatility

Over the last 12 months, Bellicum Pharmaceuticals's shares have ranged in value from as little as $0.7211 up to $12.15. A popular way to gauge a stock's volatility is its "beta".

BLCM.US volatility(beta: 1.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bellicum Pharmaceuticals's is 1.85. This would suggest that Bellicum Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bellicum Pharmaceuticals overview

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site